COR vs NUS
Cencora, Inc. and NU Skin Enterprises, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | COR | NUS |
|---|---|---|
| Revenue | $321.3B | $1.5B |
| Net income | $1.6B | $160.2M |
| Gross margin | 3.6% | 69.4% |
| Net margin | 0.5% | 10.8% |
| Return on equity | 144.3% | 22.0% |
| Diluted EPS | $7.96 | $3.18 |
| Dividend / share | $2.20 | $0.35 |
| Payout ratio | 28.1% | 7.4% |
| Free cash flow | $3.2B | $46.0M |
| Equity | $1.5B | $805.2M |
| Net debt / equity | 2.19× | −0.02× |
| Current ratio | 0.90× | 2.08× |
| Revenue CAGR 5y | 11.1% | −10.5% |
| Profit CAGR 5y | — | −3.5% |
COR bills 216.4× the revenue of NUS, and NUS keeps more of each dollar of revenue as profit (10.8% against 0.5%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | COR | NUS |
|---|---|---|
| FY2025 | $321.3B | $1.5B |
| FY2024 | $294.0B | $1.7B |
| FY2023 | $262.2B | $2.0B |
| FY2022 | $238.6B | $2.2B |
| FY2021 | $214.0B | $2.7B |
| FY2020 | $189.9B | $2.6B |
| FY2019 | $179.6B | $2.4B |
| FY2018 | $167.9B | $2.7B |
| FY2017 | $153.1B | $2.3B |
| FY2016 | $146.8B | $2.2B |
Net income by year
Bottom line
| Fiscal year | COR | NUS |
|---|---|---|
| FY2025 | $1.6B | $160.2M |
| FY2024 | $1.5B | $-146.6M |
| FY2023 | $1.7B | $8.6M |
| FY2022 | $1.7B | $104.8M |
| FY2021 | $1.5B | $147.3M |
| FY2020 | $-3.4B | $191.4M |
| FY2019 | $855.4M | $173.6M |
| FY2018 | $1.7B | $121.9M |
| FY2017 | $364.5M | $129.4M |
| FY2016 | $1.4B | $143.1M |
Advertisement
AdSense · Rectangle 336×280